254 related articles for article (PubMed ID: 27619810)
1. Usage of 1,3-β-D-Glucan for Early Detection of Invasive Mycoses and Outcome Parameter in Immunocompromised Critically Ill Patients.
Lahmer T; Held J; Rasch S; Schnappauf C; Beitz A; Schmid RM; Huber W
Mycopathologia; 2016 Dec; 181(11-12):815-821. PubMed ID: 27619810
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 1,3-β-d-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients.
Lahmer T; Neuenhahn M; Held J; Rasch S; Schmid RM; Huber W
J Crit Care; 2016 Dec; 36():259-264. PubMed ID: 27475024
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Serum Galactomannan and 1,3-Beta-D-Glucan Determination for Early Detection of Invasive Pulmonary Aspergillosis in Critically Ill Patients with Hematological Malignancies and Septic Shock.
Lahmer T; Rasch S; Schnappauf C; Beitz A; Schmid RM; Huber W
Mycopathologia; 2016 Aug; 181(7-8):505-11. PubMed ID: 27142781
[TBL] [Abstract][Full Text] [Related]
4. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.
White SK; Schmidt RL; Walker BS; Hanson KE
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009833. PubMed ID: 32693433
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of two different (1,3)-ß-d-glucan assays for diagnosis of invasive fungal diseases: A retrospective cohort study.
Zubkowicz M; Held J; Baier M; Pletz MW; Kesselmeier M; Hagel S; Bahrs C
Mycoses; 2021 Feb; 64(2):212-219. PubMed ID: 33156525
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the performance of the Dynamiker® Fungus (1-3)-β-D-Glucan Assay to assist in the diagnosis of invasive aspergillosis, invasive candidiasis and Pneumocystis pneumonia.
White PL; Price JS; Posso RB; Barnes RA
Med Mycol; 2017 Nov; 55(8):843-850. PubMed ID: 28340117
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of biomarkers: Galactomannan and 1,3-beta-D-glucan assay for the diagnosis of invasive fungal infections in immunocompromised patients from a tertiary care centre.
Singh S; Kaur H; Choudhary H; Sethi S; Malhotra P; Gupta KL; Rudramurthy SM; Chakrabarti A
Indian J Med Microbiol; 2018; 36(4):557-563. PubMed ID: 30880706
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of 1,3 Beta-D-Glucan Detection in non-HIV Immunocompromised Mechanical Ventilated Critically Ill Patients with ARDS and Suspected Pneumocystis jirovecii Pneumonia.
Lahmer T; da Costa CP; Held J; Rasch S; Ehmer U; Schmid RM; Huber W
Mycopathologia; 2017 Aug; 182(7-8):701-708. PubMed ID: 28378239
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study.
Boch T; Spiess B; Cornely OA; Vehreschild JJ; Rath PM; Steinmann J; Heinz WJ; Hahn J; Krause SW; Kiehl MG; Egerer G; Liebregts T; Koldehoff M; Klein M; Nolte F; Mueller MC; Merker N; Will S; Mossner M; Popp H; Hofmann WK; Reinwald M; Buchheidt D
Clin Microbiol Infect; 2016 Oct; 22(10):862-868. PubMed ID: 27393123
[TBL] [Abstract][Full Text] [Related]
10. Prospective Evaluation of the Fungitell® (1→3) Beta-D-Glucan Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children's Oncology Group.
Otto WR; Dvorak CC; Boge CLK; Ostrosky-Zeichner L; Esbenshade AJ; Nieder ML; Alexander S; Steinbach WJ; Dang H; Villaluna D; Chen L; Skeens M; Zaoutis TE; Sung L; Fisher BT
Pediatr Transplant; 2023 Feb; 27(1):e14399. PubMed ID: 36299233
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two β-D-glucan assays for detecting invasive fungal diseases in immunocompromised patients.
Song J; Kim S; Park J; Park Y; Kim HS
Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115415. PubMed ID: 34082306
[TBL] [Abstract][Full Text] [Related]
12. Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.
Cento V; Alteri C; Mancini V; Gatti M; Lepera V; Mazza E; Moioli MC; Merli M; Colombo J; Orcese CA; Bielli A; Torri S; Gasparini LE; Vismara C; De Gasperi A; Brioschi P; Puoti M; Cairoli R; Lombardi G; Perno CF
Mycoses; 2020 Dec; 63(12):1299-1310. PubMed ID: 32810888
[TBL] [Abstract][Full Text] [Related]
13. Detecting Invasive Fungal Disease in Surgical Patients: Utility of the (13)- β-d-Glucan Assay.
Skubic J; Taghavi S; Castillo-Angeles M; Ramsis R; Salim A; Askari R
Surg Infect (Larchmt); 2020 Jun; 21(5):461-464. PubMed ID: 31895667
[No Abstract] [Full Text] [Related]
14. β-D-Glucan Screening for Detection of Invasive Fungal Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Koltze A; Rath P; Schöning S; Steinmann J; Wichelhaus TA; Bader P; Bochennek K; Lehrnbecher T
J Clin Microbiol; 2015 Aug; 53(8):2605-10. PubMed ID: 26041896
[TBL] [Abstract][Full Text] [Related]
15. Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit?
Garnham K; Halliday CL; Rai NJ; Jayawardena M; Hasan T; Kok J; Nayyar V; Gottlieb DJ; Gilroy NM; Chen SC
Intern Med J; 2022 Mar; 52(3):426-435. PubMed ID: 32896984
[TBL] [Abstract][Full Text] [Related]
16. Performance of 1,3-β-D-glucan for diagnosing invasive fungal diseases in children.
Calitri C; Caviglia I; Cangemi G; Furfaro E; Bandettini R; Fioredda F; Amoroso L; Faraci M; Risso FM; Mattioli G; Moscatelli A; Haupt R; Castagnola E
Mycoses; 2017 Dec; 60(12):789-795. PubMed ID: 28833726
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the (1,3)-β-D-glucan assay for the diagnosis of neonatal invasive yeast infections.
Cornu M; Goudjil S; Kongolo G; Leke A; Poulain D; Chouaki T; Sendid B
Med Mycol; 2018 Jan; 56(1):78-87. PubMed ID: 28371838
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of 1,3-beta-D-glucan serum screening in patients receiving hematopoietic stem cell transplantation.
Reischies FM; Prattes J; Woelfler A; Eigl S; Hoenigl M
Transpl Infect Dis; 2016 Jun; 18(3):466-70. PubMed ID: 26992092
[TBL] [Abstract][Full Text] [Related]
19. What should be the optimal cut-off of serum 1,3-β-D-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies?
Metan G; Koç AN; Atalay A; Kaynar LG; Ozturk A; Alp E; Eser B
Scand J Infect Dis; 2012 May; 44(5):330-6. PubMed ID: 22188426
[TBL] [Abstract][Full Text] [Related]
20. Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients.
Giacobbe DR; Del Bono V; Viscoli C; Mikulska M
Expert Rev Anti Infect Ther; 2017 Dec; 15(12):1101-1112. PubMed ID: 29125373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
